AU2018297214B2 - A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response - Google Patents

A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response Download PDF

Info

Publication number
AU2018297214B2
AU2018297214B2 AU2018297214A AU2018297214A AU2018297214B2 AU 2018297214 B2 AU2018297214 B2 AU 2018297214B2 AU 2018297214 A AU2018297214 A AU 2018297214A AU 2018297214 A AU2018297214 A AU 2018297214A AU 2018297214 B2 AU2018297214 B2 AU 2018297214B2
Authority
AU
Australia
Prior art keywords
pain
compound
inflammation
cancer
inflammatory response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018297214A
Other languages
English (en)
Other versions
AU2018297214A1 (en
Inventor
Craig HARTRICK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caventure Drug Discovery Inc
Original Assignee
Caventure Drug Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caventure Drug Discovery Inc filed Critical Caventure Drug Discovery Inc
Publication of AU2018297214A1 publication Critical patent/AU2018297214A1/en
Application granted granted Critical
Publication of AU2018297214B2 publication Critical patent/AU2018297214B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dowels (AREA)
AU2018297214A 2017-07-06 2018-06-22 A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response Active AU2018297214B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529285P 2017-07-06 2017-07-06
US62/529,285 2017-07-06
PCT/US2018/038936 WO2019010014A1 (en) 2017-07-06 2018-06-22 OPIOID KAPPA AND DELTA AGONIST WITH DOUBLE ACTION LIMITED TO PERIPHERY FOR ANALGESIA IN PAIN CONDITIONS INVOLVING INFLAMMATORY RESPONSE

Publications (2)

Publication Number Publication Date
AU2018297214A1 AU2018297214A1 (en) 2020-01-16
AU2018297214B2 true AU2018297214B2 (en) 2022-09-01

Family

ID=64950308

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018297214A Active AU2018297214B2 (en) 2017-07-06 2018-06-22 A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response

Country Status (10)

Country Link
US (2) US11185551B2 (enExample)
EP (1) EP3649132B1 (enExample)
JP (1) JP7233741B2 (enExample)
KR (1) KR20200026962A (enExample)
CN (2) CN111278831A (enExample)
AU (1) AU2018297214B2 (enExample)
CA (1) CA3067398A1 (enExample)
IL (1) IL271772A (enExample)
SG (1) SG11201912036XA (enExample)
WO (1) WO2019010014A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022260648A1 (en) * 2021-06-07 2022-12-15 Uwm Research Foundation, Inc. Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0799051B1 (en) * 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
WO2002102232A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
EA201691489A1 (ru) 2014-01-24 2016-12-30 Кадила Хелзкэр Лимитед Новые гетероциклические соединения в качестве агонистов каппа-опиодиов

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shainell O. Eans et al., JOURNAL OF MEDICINAL CHEMISTRY, US, (2015-06-04), vol. 58, no. 12, doi:10.1021/jm501637c, ISSN 0022-2623, pages 4905 - 4917 *

Also Published As

Publication number Publication date
US11185551B2 (en) 2021-11-30
US20210161912A1 (en) 2021-06-03
EP3649132A4 (en) 2021-04-07
CN111278831A (zh) 2020-06-12
AU2018297214A1 (en) 2020-01-16
CA3067398A1 (en) 2019-01-10
US20220288089A1 (en) 2022-09-15
IL271772A (en) 2020-02-27
CN116440140A (zh) 2023-07-18
EP3649132A1 (en) 2020-05-13
JP7233741B2 (ja) 2023-03-07
KR20200026962A (ko) 2020-03-11
EP3649132B1 (en) 2023-12-27
SG11201912036XA (en) 2020-01-30
WO2019010014A1 (en) 2019-01-10
JP2020525548A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
CN100502858C (zh) 柚皮素及其衍生物用于制备抗心脑系统疾病产品的用途
Rastogi et al. Novel treatment modalities for painful diabetic neuropathy
AU2021204517B2 (en) Combination of opioids and n-acylethanolamines
EP2948140B1 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
AU2018297214B2 (en) A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response
Smith et al. Pain pharmacology and the pharmacological management of pain
US10357533B2 (en) Drug for the effective control of acute and or chronic pain and a method for its administration
JP2019511996A (ja) 膵臓脂肪浸潤を予防または治療し、膵臓脂肪浸潤に起因する膵臓病変、糖尿病または他の関連症状を緩和するための組成物、および方法
UA128573C2 (uk) Способи лікування підвищення маси тіла, індукованого антипсихотичними засобами, за допомогою мірикориланту
AU2013301125B2 (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
Ghodrati et al. Antinociceptive effects of fentanyl and nonopioid drugs in methocinnamox-treated rats
KR20180010475A (ko) Trpc3의 억제제를 유효성분으로 포함하는 가려움증 치료용 약제학적 조성물
TW202010496A (zh) 双那布扶林己二酸酯和乙醯胺酚的藥物製劑及治療疼痛的方法
Popoli et al. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease
Poli et al. Functional interactions between adenosine A1 and class II of metabotropic glutamate receptors in rat hippocampus
EA040799B1 (ru) Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения
BR112019024373B1 (pt) Uso de teacrina e cafeína
WO2017153935A1 (en) Composition for treating and preventing rheumatoid arthritis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ A PERIPHERALLY-RESTRICTED DUAL-ACTING KAPPA AND DELTA OPIOID AGONIST FOR ANALGESIA IN PAIN STATES INVOLVING THE INFLAMMATORY RESPONSE

FGA Letters patent sealed or granted (standard patent)